We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Next month, five Central American nations and the Dominican Republic are expected to sign a trade pact with the United States. Under the pact, known as the Central American Free-Trade Agreement, many US exports of consumer and industrial goods will become duty free in Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua and the Dominican Republic. In return, the US market will open up to many products from the six smaller countries.

Critics from the public health sector say that the agreement's strict intellectual property rights protection will make access to generic medications nearly impossible in the poorer nations. They say that the trade pact gives greater protection to patent holders and drug companies than in most previous agreements, including the World Trade Organisation's Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement.

But multinational drug companies and others defend the patent protection imposed by the pact, arguing that the measures are needed to protect investment required to turn a chemical entity into a marketable pharmaceutical product.

Link to full article in The Lancet*

*Free registration is required to view this article